Organon has started new fertility hormone phase III clinical studies
Org 36286 is a New Biological Entity. Its distinct structure and pharmacokinetic properties set Org 36286 apart from existing classes of fertility hormones and make it the first Sustained Follicle Stimulant (SFS). Org 36286 is intended for use in women undergoing controlled ovarian stimulation (COS) during infertility treatment. Worldwide, over 700,000 cycles using COS for assisted reproduction treatment for in vitro fertilization and/or intracytoplasmic sperm injection take place each year.
The LIFE clinical trial program will focus on establishing Org 36286's efficacy and safety in infertile women, as well determining its potential to simplify treatment. The LIFE program will take place in about 75 fertility clinics in Europe, USA, Canada, Asia, Latin America, and Australia.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.